This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove Behavioural Health Remove Pharma Production Remove Production Related Topics
Licensing FDA Approval Life Science Development Clinical Trials Medicine Trials Marketing Drugs Licensing More Related Topics >
article thumbnail

SparkRx: The first digital therapeutic for adolescents

pharmaphorum

MAY 9, 2022

SparkRx is designed to decrease depression in individuals aged 13 to 22 by providing a multi-week programme based on cognitive behavioural therapy (CBT) and behavioural activation protocols. “In In primary care, there are guidelines to screening for behavioural health concerns like depression annually.

Behavioural Health 135
Behavioural Health Production Life Science Development 135
article thumbnail

Orexo eyes opioid use disorder app launch before year-end

pharmaphorum

OCTOBER 2, 2020

Like its earlier digital therapies for alcohol misuse and depression , Modia’s earlier-than-expected rollout stems from legislation that has made it possible to secure reimbursement for certain digital products for psychiatric disorders during the COVID-19 pandemic.

Behavioural Health 98
Behavioural Health Production FDA Approval Pharma Production 98
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 32,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024